Andrew Bowser

Dermatologists should take ownership of screening patients for mental health concerns associated with their skin condition.

AJCC updates classifications for head and neck cutaneous squamous cell carcinoma. AJCC 8 expands criteria for cases that now qualify to be T3. Now, T3 and T4 capture more poor outcomes.

Despite recommendations to limit the use of oral antibiotics, dermatologists continue to prescribe them in high numbers, according to results of a large, retrospective analysis of U.S. prescribing trends from 2004 to 2013.

Dermatologist evaluations of patient acne photos submitted via smartphone compare favorably to in-person evaluations, a JAMA Dermatology study shows.

Some authors of AAD clinical practice guidelines received sizable payments from industry that were not completely disclosed, JAMA Dermatology Reports.

In 2018 at just five days into the New Year, a search of PubMed revealed 86 new psoriasis studies. So, who is leading the pack?

Study shows no significant difference in herpes zoster risk between psoriasis patients receiving systemic therapy and those not receiving systemic therapy.

The cost of doxycycline hyclate prescriptions increased 1,854% between 2011 and 2013 in a retrospective analysis of commercial claims data, and there was no association between market concentration and price of the oral antibiotic. Clinician or pharmacy level interventions to choose less costly oral tetracycline-class antibiotics could result in substantial cost savings.

Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials, a study shows.

Thinking of psoriasis and atopic dermatitis as a spectrum, rather than separate diseases might lead to better understanding, and potentially better treatments.

Ocular comorbidity risk is already high in patients with atopic dermatitis and may increase even further as biologic agents are introduced, a study shows.

Until recently, atopic dermatitis treatments were primarily limited to topical corticosteroids and systemic immunosuppressants. Now, two new therapies have reached clinical practice. Nineteen more are in development.

Early trial results show a significant reduction of itch with the oral NK-1 antagonist serlopitant

Dupilumab plus topical corticosteroids safe and effective after failure of cyclosporine in moderate-to-severe atopic dermatitis

Metabolomics could provide new statistical methods to help monitor psoriasis disease and progression.